Bencycloquidium bromide nasal spray is effective and safe for persistent allergic rhinitis: a phase III, multicenter, ra
- PDF / 1,534,917 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 79 Downloads / 214 Views
RHINOLOGY
Bencycloquidium bromide nasal spray is effective and safe for persistent allergic rhinitis: a phase III, multicenter, randomized, double‑blinded, placebo‑controlled clinical trial Zihan Jiang1 · Hao Xiao1 · Shixi Liu1 · Gang He2 · Guohua Hu3 · Xueyuan Zhang4 · Qinna Zhang5 · Jichuan Chen6 · Chang Lin7 · Jianping Liang8 · Mingli Guo9 · Xuping Xiao10 · Weiguo Xue11 · Pin Dong12 · Yongwang Huang13 · Zhuang Lian14 · Guolin Tan15 · Jia He16 · Yuanyuan Pan17 · Juan Meng1 Received: 20 March 2020 / Accepted: 30 June 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Purpose To investigate the efficacy and safety of bencycloquidium bromide nasal spray (BCQB) in patients with persistent allergic rhinitis (PAR). Methods We enrolled 720 patients from 15 hospitals across China and randomly assigned them into BCQB group or placebo group (90 μg per nostril qid) to receive a 4-week treatment. Visual analog scale (VAS) for rhinorrhea, sneezing, nasal congestion, itching and overall symptoms were recorded by patients every day. Anterior rhinoscopy scoring was completed by doctors on every visit. Adverse events were recorded in detail. Results A total of 354 and 351 patients were included in BCQB group and in placebo group. Baseline information was comparable. At the end of the trial, the decrease of VAS for rhinorrhea from baseline was 4.83 ± 2.35 and 2.46 ± 2.34 in BCQB group and placebo group, respectively (P
Data Loading...
